TuHURA Biosciences Inc (HURA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, TuHURA Biosciences Inc (HURA) has a cash flow conversion efficiency ratio of -0.190x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.41 Million) by net assets ($23.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HURA cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
TuHURA Biosciences Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how TuHURA Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
TuHURA Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TuHURA Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
REDELFI SPA
F:B0Z
|
N/A |
|
Solteam Electronics Co Ltd
TWO:3484
|
0.029x |
|
Arsan Tekstil Ticaret ve Sanayi AS
IS:ARSAN
|
0.015x |
|
Adisyn Ltd
AU:AI1
|
-0.042x |
|
Ally Leasehold Real Estate Investment Trust
BK:ALLY
|
0.051x |
|
GPT Healthcare Ltd
NSE:GPTHEALTH
|
0.073x |
|
Santech Holdings Limited
NASDAQ:STEC
|
N/A |
|
Hwa Fong Rubber Ind Co Ltd
TW:2109
|
0.062x |
Annual Cash Flow Conversion Efficiency for TuHURA Biosciences Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of TuHURA Biosciences Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see HURA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $14.59 Million | $-14.73 Million | -1.009x | -121.92% |
| 2024-06-30 | $-1.56 Million | $-7.18 Million | 4.604x | +854.42% |
| 2023-06-30 | $12.30 Million | $-7.51 Million | -0.610x | -106.95% |
| 2022-06-30 | $-747.82K | $-6.56 Million | 8.777x | +592.39% |
| 2021-06-30 | $10.58 Million | $-18.86 Million | -1.782x | +94.09% |
| 2020-06-30 | $263.00K | $-7.93 Million | -30.144x | -837.35% |
| 2019-06-30 | $1.97 Million | $-6.33 Million | -3.216x | -77.44% |
| 2018-06-30 | $5.44 Million | $-9.85 Million | -1.812x | -48.68% |
| 2017-06-30 | $6.58 Million | $-8.02 Million | -1.219x | -15.10% |
| 2016-06-30 | $4.86 Million | $-5.15 Million | -1.059x | -122.58% |
| 2015-06-30 | $-821.49K | $-3.85 Million | 4.690x | -- |
About TuHURA Biosciences Inc
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration tri… Read more